This Article  • References  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Contact me when this article is cited  Related Content  • Similar articles in this journal

Clinical Evaluation

GEORGE M. KALMANSON, M.D.; ERNST J. DRENICK, M.D.; MAXWELL J. BINDER, M.D.; LEON ROSOVE, M.D.

AMA Arch Intern Med. 1955;95(6):819-822.

	Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

Although many drugs have been advocated for the treatment of angina pectoris, only the nitrites have proved unequivocally useful. Glyceryl trinitrate (nitroglycerin) promptly relieves the pain of angina pectoris, but its value as a prophylactic agent is limited by the short duration of its action. For this reason, various related compounds have been developed in an effort to find a long-acting drug which would prevent anginal pain.

Von Oettingen and his co-workers ¹ studied the pharmacology and toxicity of pentaerythritol (Peritrate) tetranitrate in 1944. Subsequently, several favorable reports on its use in angina pectoris were published in Europe.* Winsor and Humphreys ⁴ studied the effect of pentaerythritol tetranitrate on 125 patients who had angina pectoris. They found that an average dose of 10 mg. three times daily produced satisfactory prevention of precordial pain in 78.4% of the patients. Glyceryl trinitrate requirement was reduced; exercise tolerance was increased, and the S-T . . . [Full Text PDF of this Article]

Author Affiliations
Los Angeles

From the Medical Service, Veterans Administration Center, and the Department of Medicine, University of California at Los Angeles.